<i>pat-2</i> mutants contain more apoptotic cells during mid-embryogenesis than the wild-type.

aThe number of cell corpses in each genotype was scored at the indicated embryonic stage. bEmbryos that showed normal embryogenesis were scored as nonPat and those paralyzed at the 2-fold stage were scored as Pat. cHomozygous progeny of unc-79(e1068) pat-2(st567)/dpy-17(e164) heterozygous mothers. dNon-transgenic progeny of unc-79(e1068) pat-2(st567); Ex[Ppat-2pat-2::gfp] mothers. eNon-transgenic progeny of unc-79(e1068) pat-2(st567); ced-3(n717); Ex[Ppat-2pat-2::gfp] mothers. fHomozygous progeny of pat-3(st564)/qC1 dpy-19(e1259) glp-1(q339) heterozygous mothers. pat-2, ina-1, and pat-3 single mutants were compared to the wild-type (**p<0.001) and double mutants were compared to the corresponding single mutants (#p<0.05 and ##p<0.001) at each stage. All comparisons were performed using the unpaired t test. The cell corpse numbers of homozygous pat-2(st567)d embryos treated with pat-2 RNAi are not distinguishable from those of pat-2(st567)d or pat-2(RNAi) embryos at the same stage. Data are presented as the mean ± standard deviation (SD) for >15 embryos per stage.